Compare Amgen, Inc. (AMGN) vs Bit Digital Inc (BTBT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Bit Digital Inc — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Bit Digital Inc trades at $1.66 (market cap $599.01M). The key difference: Amgen, Inc. is far larger — about 327.4× Bit Digital Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while Bit Digital Inc pays none. Which is the better fit depends on your goals.
| AMGN | BTBT | |
|---|---|---|
Market Cap | $196.12B | $599.01M |
Sector | Health | Technology |
52-Week High | $388.16 | $4.22 |
52-Week Low | $271.18 | $1.27 |
Enterprise Value | $241.41B | $888.32M |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
BTBT trades at $1.69, showing slight positive momentum with a 0.6% daily gain, but faces a bearish technical outlook with 15 sell signals versus 3 buys. The company reported a net loss of $80.32 million in 2025, with revenue of $113.56 million, and has missed earnings expectations for three consecutive quarters. Recent strategic moves include a $100 million loan facility for WhiteFiber and a $20 million Ethereum purchase to bolster its asset position.
The outlook remains challenging due to persistent losses and negative profit margins, though analyst consensus is unanimously bullish with 2 buy ratings. Key risks include execution challenges in AI infrastructure investments, reliance on financing for cash flow, and sensitivity to cryptocurrency market volatility impacting its strategic asset holdings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Bit Digital Inc
Bit Digital is a sustainability-focused digital asset production company. It primarily engages in Bitcoin mining and Ethereum staking while also providing high-performance computing (HPC) infrastructure for AI applications.
Read more on BTBT →
